President Donald Trump’s recent executive order targeting prescription drug pricing is sparking legal concerns across the healthcare and policy landscape. The “Most Favored Nation” (MFN) pricing model ties the cost of certain U.S. drugs to the lower prices paid by other developed nations. While the goal of lowering pharmaceutical costs is widely supported by the public, legal experts are raising red flags about how this order aligns with current federal laws, administrative procedures, and trade agreements.
The Basics of the Executive Order
The MFN executive order mandates that Medicare pay the same lowest price for select prescription drugs as paid by countries such as Canada, the UK, and Germany. This effort is intended to address the long-standing issue of Americans paying significantly more for medications compared to citizens in other wealthy nations.
The order primarily affects Medicare Part B and Part D programs, which cover doctor-administered and pharmacy-dispensed medications, respectively. Trump argued that the U.S. has been “subsidizing” the rest of the world’s drug costs for decades. Supporters say the move could drive down prices by 30–80% for commonly prescribed medications.
Concerns About Statutory Authority
One of the primary legal concerns centers around whether the executive branch has the authority to enforce international price indexing without direct action from Congress. While the Inflation Reduction Act of 2022 granted Medicare new negotiation power, it’s unclear whether this executive order exceeds the scope of that law.
Critics argue that only Congress can fundamentally alter how Medicare calculates reimbursement rates. Past judicial rulings have emphasized that significant policy changes must be backed by clear legislative mandates. Therefore, legal experts warn that the MFN policy could face lawsuits over claims of executive overreach.
